帕金森病的初始药物治疗策略
Initial Medical Treatment for Parkinson’s Disease
DOI: 10.12677/jcpm.2025.41008, PDF,   
作者: 赵美丽：内蒙古医科大学临床学院，内蒙古 包头；刘佳慧：包头市中心医院神经内科，内蒙古 包头
关键词: 帕金森病；药物治疗；不良反应；疗效；Parkinson’s Disease； Pharmacological Treatment； Adverse Reaction； Efficacy
摘要: 帕金森病(Parkinson’s Disease, PD)是最常见的神经变性运动障碍，目前药物治疗仍是目前临床上控制和缓解其症状的主要方法。本文综述主要梳理帕金森病患者起始用药管理及相关不良反应和疗效，以期为临床医生提供合理的药物选择，制定精准的治疗方案，旨为更好地医治患者，提高生存质量。
Abstract: Parkinson’s disease (PD) is the most common neurodegenerative movement disorder, affecting millions of adults worldwide. This review mainly reviews the initial medication management and related adverse reactions and efficacy of patients with Parkinson’s disease, in order to provide clinicians with reasonable drug choices and formulate precise treatment plans, with the aim of better treating patients and improving the quality of life.
文章引用：赵美丽, 刘佳慧. 帕金森病的初始药物治疗策略[J]. 临床个性化医学, 2025, 4(1): 46-53. https://doi.org/10.12677/jcpm.2025.41008

参考文献

[1] Fox, S.H., Katzenschlager, R., Lim, S., Barton, B., de Bie, R.M.A., Seppi, K., et al. (2018) International Parkinson and Movement Disorder Society Evidence-Based Medicine Review: Update on Treatments for the Motor Symptoms of Parkinson’s Disease. Movement Disorders, 33, 1248-1266. [Google Scholar] [CrossRef] [PubMed]
[2] Pringsheim, T., Day, G.S., Smith, D.B., Rae-Grant, A., Licking, N., Armstrong, M.J., et al. (2021) Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary. Neurology, 97, 942-957. [Google Scholar] [CrossRef] [PubMed]
[3] Connolly, B.S. and Lang, A.E. (2014) Pharmacological Treatment of Parkinson Disease. Journal of the American Medical Association, 311, Article 1670. [Google Scholar] [CrossRef] [PubMed]
[4] Rogers, G., Davies, D., Pink, J. and Cooper, P. (2017) Parkinson’s Disease: Summary of Updated NICE Guidance. British Medical Journal, 358, j1951. [Google Scholar] [CrossRef] [PubMed]
[5] Grimes, D., Fitzpatrick, M., Gordon, J., Miyasaki, J., Fon, E.A., Schlossmacher, M., et al. (2019) Canadian Guideline for Parkinson Disease. Canadian Medical Association Journal, 191, E989-E1004. [Google Scholar] [CrossRef] [PubMed]
[6] Calabresi, P., Filippo, M.D., Ghiglieri, V., Tambasco, N. and Picconi, B. (2010) Levodopa-Induced Dyskinesias in Patients with Parkinson’s Disease: Filling the Bench-to-Bedside Gap. The Lancet Neurology, 9, 1106-1117. [Google Scholar] [CrossRef] [PubMed]
[7] Aquino, C.C. and Fox, S.H. (2014) Clinical Spectrum of Levodopa-Induced Complications. Movement Disorders, 30, 80-89. [Google Scholar] [CrossRef] [PubMed]
[8] Olanow, C.W., Watts, R.L. and Koller, W.C. (2001) An Algorithm (Decision Tree) for the Management of Parkinson’s Disease. Neurology, 56, S1-S88. [Google Scholar] [CrossRef] [PubMed]
[9] Fereshtehnejad, S., Shafieesabet, M., Farhadi, F., Hadizadeh, H., Rahmani, A., Naderi, N., et al. (2015) Heterogeneous Determinants of Quality of Life in Different Phenotypes of Parkinson’s Disease. PLOS ONE, 10, e0137081. [Google Scholar] [CrossRef] [PubMed]
[10] Fahn, S. and Bressman, S.B. (1984) Should Levodopa Therapy for Parkinsonism Be Started Early or Late? Evidence against Early Treatment. Canadian Journal of Neurological Sciences, 11, 200-205. [Google Scholar] [CrossRef] [PubMed]
[11] Melamed, E. (1986) Initiation of Levodopa Therapy in Parkinsonian Patients Should Be Delayed until the Advanced Stages of the Disease. Archives of Neurology, 43, 402-405. [Google Scholar] [CrossRef] [PubMed]
[12] Warren Olanow, C., Kieburtz, K., Rascol, O., Poewe, W., Schapira, A.H., Emre, M., et al. (2013) Factors Predictive of the Development of Levodopa-Induced Dyskinesia and Wearing-Off in Parkinson’s Disease. Movement Disorders, 28, 1064-1071. [Google Scholar] [CrossRef] [PubMed]
[13] Howie, E.K., McVeigh, J.A. and Straker, L.M. (2016) Comparison of Compliance and Intervention Outcomes between Hip-and Wrist-Worn Accelerometers during a Randomized Crossover Trial of an Active Video Games Intervention in Children. Journal of Physical Activity and Health, 13, 964-969. [Google Scholar] [CrossRef] [PubMed]
[14] PD MED Collaborative Group (2014) Long-Term Effectiveness of Dopamine Agonists and Monoamine Oxidase B Inhibitors Compared with Levodopa as Initial Treatment for Parkinson's Disease (PD MED): A Large, Open-Label, Pragmatic Randomized Trial. The Lancet, 384, 1196-1205. [Google Scholar] [CrossRef] [PubMed]
[15] Verschuur, C.V.M., Suwijn, S.R., Boel, J.A., Post, B., Bloem, B.R., van Hilten, J.J., et al. (2019) Randomized Delayed-Start Trial of Levodopa in Parkinson’s Disease. New England Journal of Medicine, 380, 315-324. [Google Scholar] [CrossRef] [PubMed]
[16] Bressman, S. and Saunders-Pullman, R. (2019) When to Start Levodopa Therapy for Parkinson’s Disease. New England Journal of Medicine, 380, 389-390. [Google Scholar] [CrossRef] [PubMed]
[17] Yokochi, F. (2000) Pharmacological Treatment of Parkinsonian Tremor. Nihon Rinsho, 58, 2091-2095.
[18] Ferreira, J.J., Katzenschlager, R., Bloem, B.R., Bonuccelli, U., Burn, D., Deuschl, G., et al. (2012) Summary of the Recommendations of the EFNS/MDS-ES Review on Therapeutic Management of Parkinson’s Disease. European Journal of Neurology, 20, 5-15. [Google Scholar] [CrossRef] [PubMed]
[19] Muzerengi, S. and Clarke, C.E. (2015) Initial Drug Treatment in Parkinson’s Disease. British Medical Journal, 74, h4669. [Google Scholar] [CrossRef] [PubMed]
[20] Espay, A.J. and Lang, A.E. (2017) Common Myths in the Use of Levodopa in Parkinson Disease. JAMA Neurology, 74, 633-634. [Google Scholar] [CrossRef] [PubMed]
[21] Ondo, W.G., Shinawi, L. and Moore, S. (2010) Comparison of Orally Dissolving Carbidopa/Levodopa (Parcopa) to Conventional Oral Carbidopa/Levodopa: A Single-Dose, Double-Blind, Double-Dummy, Placebo-Controlled, Crossover Trial. Movement Disorders, 25, 2724-2727. [Google Scholar] [CrossRef] [PubMed]
[22] Dhall, R. and Kreitzman, D.L. (2016) Advances in Levodopa Therapy for Parkinson Disease. Neurology, 86, S13-S24. [Google Scholar] [CrossRef] [PubMed]
[23] Frequin, H.L., Schouten, J., Verschuur, C.V.M., Suwijn, S.R., Boel, J.A., Post, B., et al. (2023) Levodopa Response in Patients with Early Parkinson Disease. Neurology, 100, e367-e376. [Google Scholar] [CrossRef] [PubMed]
[24] Chou, K.L., Stacy, M., Simuni, T., Miyasaki, J., Oertel, W.H., Sethi, K., et al. (2018) The Spectrum of “off” in Parkinson's Disease: What Have We Learned over 40 Years? Parkinsonism & Related Disorders, 51, 9-16. [Google Scholar] [CrossRef] [PubMed]
[25] Kulisevsky, J., Oliveira, L. and Fox, S.H. (2018) Update in Therapeutic Strategies for Parkinson’s Disease. Current Opinion in Neurology, 31, 439-447. [Google Scholar] [CrossRef] [PubMed]
[26] Frampton, J.E. (2014) Pramipexole Extended-Release: A Review of Its Use in Patients with Parkinson’s Disease. Drugs, 74, 2175-2190. [Google Scholar] [CrossRef] [PubMed]
[27] Onofrj, M., Bonanni, L., De Angelis, M.V., Anzellotti, F., Ciccocioppo, F. and Thomas, A. (2009) Long Half-Life and Prolonged-Release Dopamine Receptor Agonists: A Review of Ropinirole Prolonged-Release Studies. Parkinsonism & Related Disorders, 15, S85-S92. [Google Scholar] [CrossRef] [PubMed]
[28] Schapira, A.H.V., Fox, S.H., Hauser, R.A., Jankovic, J., Jost, W.H., Kenney, C., et al. (2017) Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients with Parkinson Disease and Motor Fluctuations. JAMA Neurology, 74, Article 216. [Google Scholar] [CrossRef] [PubMed]
[29] Fabbrini, G., Abbruzzese, G., Marconi, S. and Zappia, M. (2012) Selegiline. Clinical Neuropharmacology, 35, 134-140. [Google Scholar] [CrossRef] [PubMed]
[30] Larsen, J.P., Boas, J. and Erdal, J.E. (1999) Does Selegiline Modify the Progression of Early Parkinson’s Disease? Results from a Five-Year Study. European Journal of Neurology, 6, 539-547. [Google Scholar] [CrossRef] [PubMed]
[31] Blanchet, P.J., Metman, L.V. and Chase, T.N. (2003) Renaissance of Amantadine in the Treatment of Parkinson’s Disease. Advances in Neurology, 91, 251-257.
[32] Wu, J., Lu, A.D., Zhang, L.P., Zuo, Y.X. and Jia, Y.P. (2019) Study of Clinical Outcome and Prognosis in Pediatric Core Binding Factor-Acute Myeloid Leukemia. Chinese Journal of Hematology, 40, 52-57.
[33] Khlebtovsky, A., Steiner, I., Treves, T. and Djaldetti, R. (2019) Effect of Repeated Intravenous Amantadine Infusions in Patients with Parkinson’s Disease: An Open-Label Pilot Study. Clinical and Translational Science, 12, 586-590. [Google Scholar] [CrossRef] [PubMed]
[34] 曹开谊. 盐酸苯海索治疗帕金森病与帕金森综合征探究[J]. 中国处方药, 2015, 13(5): 84-85.